Skip to main content
海昇药业 logo

海昇药业 — Investor Relations & Filings

Ticker · 920656 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 271 across all filing types
Latest filing 2025-09-07 Share Issue/Capital Cha…
Country CN China
Listing Beijing Stock Exchange 920656

About 海昇药业

https://www.zcpc.net/

Zhejiang Haisheng Pharmaceutical Co., Ltd. specializes in the research, development, production, and sale of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The company's core product portfolio includes antipyretic and analgesic medications, cardiovascular agents, and various specialty chemical intermediates. It is recognized as a major global supplier of Naproxen and Naproxen Sodium. Haisheng Pharmaceutical maintains rigorous quality control systems compliant with international standards, including Good Manufacturing Practice (GMP) certifications. The company serves a diverse global clientele, providing high-purity chemical components essential for finished dosage form manufacturing. Its technical expertise focuses on chemical synthesis and process optimization to ensure stable supply chains for the pharmaceutical industry.

Recent filings

Filing Released Lang Actions
股票解除限售公告
Share Issue/Capital Change Classification · 95% confidence The document is a stock-related announcement from Zhejiang Haisheng Pharmaceutical Co., Ltd. It details the lifting of trading restrictions on a specific number of shares, including the shareholders involved, reasons for lifting restrictions, and the updated share capital structure. The document includes no financial statements or performance data, nor does it present a report or presentation. It is a regulatory announcement about share status changes, specifically about lifting share lock-up restrictions. This fits best under the category of Share Issue/Capital Change (SHA), which covers announcements regarding share capital changes such as lifting restrictions on shares.
2025-09-07 Chinese
关于使用闲置自有资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Zhejiang Haisheng Pharmaceutical Co., Ltd. regarding the progress of using idle proprietary funds to purchase wealth management products. It includes specifics about authorized entrusted wealth management, amounts, counterparties, product types, expected yields, terms, and risk controls. The document is a formal disclosure about the company's cash management and investment activities, including approvals from board and shareholder meetings. It does not contain financial statements, earnings data, or management discussion of financial results. It is not a report like an annual or interim report, nor is it a call transcript or governance document. It is an update on financing-related activities, specifically the use of company funds for investment in financial products. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length (7727 characters) and detailed content support this classification with high confidence.
2025-09-07 Chinese
关于使用部分闲置募集资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zhejiang Haisheng Pharmaceutical Co., Ltd. regarding the progress of using part of idle raised funds to purchase financial products. It details the authorization, amounts, types of financial products purchased, risk control measures, and related disclosures. The document is a regulatory announcement about the company's cash management and investment activities using idle raised funds, including specific transaction details and compliance with stock exchange rules. It does not contain comprehensive financial statements, audit opinions, or detailed management analysis. It is not a full financial report, earnings release, or management discussion. The document is a regulatory disclosure about capital use and investment activities, fitting best into the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about financing activities rather than just a brief notice or certification, so it is not RNS or RPA. Therefore, the classification is CAP with high confidence.
2025-09-07 Chinese
2025年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "半年度报告" which translates to "Half-Year Report" or "Interim Report" for the period January 1, 2025 to June 30, 2025. It contains detailed financial data including income, profit, assets, liabilities, cash flow, and operational analysis. It also includes sections on company overview, accounting data, business overview, risk factors, and environmental information. The length is substantial (15,000 characters) and it contains actual financial statements and substantive financial analysis. It is not a brief announcement or a certification letter. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2025
2025-08-20 Chinese
第四届董事会第二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the company's fourth board of directors' second meeting. It includes details about the meeting's time, place, attendees, and the voting results on specific agenda items. The document references other reports (2025 semi-annual report and a special report on fundraising use) that are disclosed elsewhere, indicating this document itself is not the report but an announcement of board decisions. The content focuses on board meeting resolutions and governance procedures rather than financial data or report content. Therefore, it fits best under Board/Management Information (MANG). The document length is short (1222 characters), consistent with a meeting resolution announcement rather than a full report.
2025-08-20 Chinese
长江证券承销保荐有限公司关于浙江海昇药业股份有限公司2025年半年度持续督导跟踪报告
Regulatory Filings Classification · 85% confidence The document is titled “2025 年半年度持续督导跟踪报告” issued by the sponsor (保荐机构) detailing its ongoing supervisory work, reviews of disclosures, fund usage oversight, site inspections, special opinions and risk factors. It is not the company’s own interim financial report (IR), but a regulatory compliance tracking report by the sponsoring underwriter. It is substantive and not merely an announcement, yet does not fit any financial statement category, making it a general regulatory filing.
2025-08-20 Chinese

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.